ReviewOpen access journal of urology2010
Social, economic, and health utility considerations in the treatment of overactive bladder.
Review in Open access journal of urology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02701010 (Comparative Effectiveness of Three Different Teaching Methods in Behavioural Therapy Program for Female Overactive Bladder), which is not on this map. Cited by 27 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Comparative Effectiveness of Three Different Teaching Methods in Behavioural Therapy Program for Female Overactive Bladder: A Randomized Controlled Trial
Who cites it
27 citing papers in PubMed, 7 syntheses or guidelines pooled it, 42 citations in OpenAlex.
- Global Prevalence of Overactive Bladder: A Systematic Review and Meta-analysis.International urogynecology journal · 2025Pooled it
- Pooled it
- Clinical outcomes of botulinum toxin A management for neurogenic detrusor overactivity: meta-analysis.Renal failure · 2019Pooled it
- Characterizing the Health-Related Quality of Life Burden of Overactive Bladder Using Disease-Specific Patient-Reported Outcome Measures: A Systematic Literature Review.Advances in therapy · 2019Pooled it
- The effect of onabotulinumtoxinA according to site of injection in patients with overactive bladder: a systematic review and meta-analysis.World journal of urology · 2018Pooled it
- Efficacy and safety of onabotulinumtoxinA in treating neurogenic detrusor overactivity: a systematic review and meta-analysis.Chinese medical journal · 2015Pooled it
- The efficacy and safety of mirabegron in treating OAB: a systematic review and meta-analysis of phase III trials.International urology and nephrology · 2014Pooled it
- Prevalence and risk factors of overactive bladder syndrome among Egyptian medical students, and its impact on health-related quality of life, cross-sectional study.Scientific reports · 2026Observational
- Effects ofFood science & nutrition · 2025Article
- Prevalence of Urinary Incontinence and Overactive Bladder Among Female University Students in Kazakhstan.Epidemiologia (Basel, Switzerland) · 2025Article
- Long-term follow-up of intravesical abobotulinumtoxinA (Dysport®) injections in women with idiopathic detrusor overactivity.Asian journal of urology · 2024Article
- Detrusor overactivity assessment using ultrasound bladder vibrometry.Physiological measurement · 2021Article
- Association of decreased grip strength with lower urinary tract symptoms in women: a cross-sectional study from Korea.BMC women's health · 2021Article
- Extensive impact of COVID-19 pandemic on pelvic floor dysfunctions care: A nationwide interdisciplinary survey.Neurourology and urodynamics · 2021Article
- Pharmacological Management of Urinary Incontinence: Current and Emerging Treatment.Clinical pharmacology : advances and applications · 2021Review
- Botulinum toxin in low urinary tract disorders - over 30 years of practice (Review).Experimental and therapeutic medicine · 2020Review
- Cost Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in Colombia.PharmacoEconomics - open · 2020Article
- Is nocturnal enuresis a predisposing factor for the overactive bladder?Turkish journal of medical sciences · 2019Observational
- Urothelial Senescence in the Pathophysiology of Diabetic Bladder Dysfunction-A Novel Hypothesis.Frontiers in surgery · 2018Article
- A systematic review and meta-analysis of effectiveness and safety of therapy for overactive bladder using botulinum toxin A at different dosages.Oncotarget · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Overactive bladder (OAB) is a highly prevalent urinary syndrome with a profound impact on quality of life (QoL) of affected patients and their family because of its adverse effects on social, sexual, interpersonal, and professional function. Cost-of-illness analyses showed the huge economic burden related to OAB for patients, public healthcare systems, and society, secondary to both direct and indirect costs; however, intangible costs related to QoL impact are usually omitted from these analyses. Recently many novel treatment modalities have been introduced and the need to apply the modern methodology of health technology assessment to these treatment strategies was immediately clear in order to evaluate objectively their value in term of both improvement in length/quality of life and costs. Health utilities are instruments that allow a measurement of QoL and its integration in the economic evaluation using the quality-adjusted life-years model and cost-utility analysis. The development of suitable instruments for quantifying utility in the specific group of OAB patients is vitally important to extend the application of cost-utility analysis in OAB and to guide healthcare resources allocation for this disorder. Studies are required to define the cost-effectiveness of available pharmacological and nonpharmacological therapy options for this disorder.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.